Rewriting the Future of RNA Therapy
Rznomics Inc. (standing for Ribozyme and Omics) is a South Korean biopharmaceutical company founded in 2017 by Professor Seong-Wook Lee at Dankook University, Yongin, South Korea. The company develops RNA-based gene therapies targeting oncology, degenerative diseases, and genetic diseases using its proprietary trans-splicing ribozyme RNA platform. Rznomics has attracted significant partnerships, including a $1.3 billion out-licensing deal with Eli Lilly focused on RNA editing for hearing loss, and is preparing for a Kosdaq IPO.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2023
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
